Following its strategic review, and off the back of two critical clinical trial updates - the opening of Cynata’s acute Graft-versus-host disease trial for enrolment and the approval of its Phase 1 clinical trial in kidney transplant patients - CEO Dr Kilian Kelly sat down with Kalkine Media to discuss the milestones.
Cynata has received regulatory approval from the Competent (regulatory) Authority in the Netherlands for a Phase 1 trial of CYP-001 in kidney transplant patients. Professor Rabelink, who is leading the trial, said it aims to alleviate anti-rejection drug side effects which would be of huge benefit to transplant patients as the side effects of immunosuppressants can be very devastating.
Listen to Cynata’s CEO and MD, Dr Kilian Kelly, provide an overview of the recently completed strategic review, and responses to investors’ questions.
Following the completion of a strategic review of Cynata’s clinical development portfolio, CEO Dr Kilian Kelly sat down with Proactive Investors to discuss the review and his direction for the Company. Watch the interview here.
Or read more about it on the Cairns Post here.
Having recently completed a strategic review of its clinical development portfolio under the new leadership of Dr Kilian Kelly, CEO & Managing Director, he outlines to Ausbiz what investors can expect from the Cynata in the near and long-term. Watch the interview here (start at 18.37)